Syneron Medical Intros Evolastin - Analyst Blog
03 Febrero 2012 - 11:56AM
Zacks
Aesthetic products company Syneron Medical
(ELOS) has commenced the launch of its new skin remodeling
procedure. The treatment procedure dubbed “evolastin” is the first
energy-based dermal remodeling procedure which delivers controlled
radio frequency energy directly to the deep dermal layer to
stimulate its natural production of collagen, elastin and
hyaluronic acid in one treatment.
Collagen is a naturally occurring protein which keeps skin
healthy while Elastin (a complimentary protein to collagen) helps
to maintain skin flexibility. Hyaluronic acid moisturizes skin and
reduces wrinkles.
Unlike the conventional energy-based therapy procedures which
reach the deep layer of the skin (or dermis) through surface,
evolastin places the entire energy directly at the base of the
dermis using insulated microneedles, thereby creating a unique
wound healing response.
The procedure is generally performed under local anesthetic and
takes roughly an hour, enabling patients to go home safely
following treatment and return to normal activities within a day.
Results from a recently published study by leading dermatologists
demonstrated the unique benefits of evolastin for patients looking
for an alternative to address the loss of tautness and elasticity
of skin most common with age.
Syneron offers a comprehensive product portfolio and a global
distribution setup. Its knowledge allows medical practitioners to
provide sophisticated solutions for a wide range such as wrinkle
reduction, hair removal and body contouring. The company faces some
competition from Cutera (CUTR) among others.
Syneron’s product line-up includes items for skincare for both
the home-use and professional segments. The company markets and
supports its products in about 86 nations.
Syneron’s revenues for third-quarter fiscal 2011 surged 28% year
over year to $57 million, fueled by robust sales from its Emerging
Business Units (“EBU”) segment. Revenues from the EBU unit
increased nearly six-fold year over year in the quarter. Sales from
its core Aesthetic Devices division climbed 19%.
However, the company’s losses widened to $40.1 million (or $1.14
a share) in the quarter from $5.2 million (or 15 cents a share) a
year ago, hurt by costs associated with legal settlement with
Palomar Medical (PMTI). Syneron is scheduled to
report its fourth quarter results on February 9.
CUTERA INC (CUTR): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
PALOMAR MED TEC (PMTI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024